[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA2273203A1 - Inhibition antisens de molecules d'adhesion humaines - Google Patents

Inhibition antisens de molecules d'adhesion humaines Download PDF

Info

Publication number
CA2273203A1
CA2273203A1 CA002273203A CA2273203A CA2273203A1 CA 2273203 A1 CA2273203 A1 CA 2273203A1 CA 002273203 A CA002273203 A CA 002273203A CA 2273203 A CA2273203 A CA 2273203A CA 2273203 A1 CA2273203 A1 CA 2273203A1
Authority
CA
Canada
Prior art keywords
oligonucleotide
selectin
vcam
icam
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002273203A
Other languages
English (en)
Inventor
Glenn D. Hoke
Matthews O. Bradley
Taffy J. Williams
Che-Hung Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Dyad Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyad Pharmaceutical Corp filed Critical Dyad Pharmaceutical Corp
Publication of CA2273203A1 publication Critical patent/CA2273203A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un traitement contre des maladies et des pathologies associées chez l'homme à des inflammations, à savoir, notamment l'acné, le psoriasis, l'arthrite, le rejet de greffe, les blessures, les brûlures, le choc septique et les complications inflammatoires du choc. L'invention concerne également un procédé permettant d'inhiber sélectivement l'expression des produits de transcription d'ARNm de la molécule d'adhésion intercellulaire humaine ICAM-1, de la sélectine E humaine ou de la molécule d'adhésion cellulaire vasculaire humaine VCAM-1 au moyen d'au moins un oligonucléotide complémentaire d'au moins une partie des ARNm de l'ICAM-1 humaine, de la sélectine E humaine ou de la VCAM-1 humaine. L'invention concerne en outre, non seulement des oligonucléotides complémentaires de certaines parties des ARNm de l'ICAM-1 humaine, de la sélectine E humaine ou de la VCAM-1 humaine, mais aussi des compositions comprenant ces oligonucléotides.
CA002273203A 1996-12-02 1996-12-02 Inhibition antisens de molecules d'adhesion humaines Abandoned CA2273203A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1996/019194 WO1998024797A1 (fr) 1996-12-02 1996-12-02 Inhibition antisens de molecules d'adhesion humaines

Publications (1)

Publication Number Publication Date
CA2273203A1 true CA2273203A1 (fr) 1998-06-11

Family

ID=22256225

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002273203A Abandoned CA2273203A1 (fr) 1996-12-02 1996-12-02 Inhibition antisens de molecules d'adhesion humaines

Country Status (5)

Country Link
EP (1) EP0950060A4 (fr)
JP (1) JP2001505432A (fr)
AU (1) AU1564897A (fr)
CA (1) CA2273203A1 (fr)
WO (1) WO1998024797A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19844111A1 (de) * 1998-09-25 2000-04-20 Deutsches Krebsforsch Antisense-Sequenzen für die Hemmung der Expression des Adhäsionsmoleküls ICAM-1
DE59904870D1 (de) * 1998-09-25 2003-05-08 Deutsches Krebsforsch Antisense-sequenzen für die hemmung der expression des adhäsionsmoleküls icam-1
US6114517A (en) * 1998-12-10 2000-09-05 Isis Pharmaceuticals Inc. Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
EP1146908B1 (fr) 1999-01-27 2005-08-03 Becker, David, Dr. Formulations comportant des nucleotides anti-sens de connexine
DE10019252A1 (de) * 2000-04-18 2001-10-31 Klaus Karl Degitz Polydesoxyribonukleotide zur Hemmung der ICAM-1-Genexpression
DE10141443B4 (de) * 2001-08-23 2007-02-01 Christos C. Prof. Dr. Zouboulis Verwendung von molekularbiologisch hergestellten, nicht-viralen Wirkstoffen zur Behandlung der Akne
HUE045953T2 (hu) 2003-12-03 2020-01-28 Ocunexus Therapeutics Inc Connexin 43 elleni gátló vegyületek és azok alkalmazási eljárásai szem szaruhártya trauma kezelésében
KR102073629B1 (ko) 2005-02-03 2020-02-05 코다 테라퓨틱스 (엔지) 리미티드 항-코넥신 화합물 및 그의 용도
CN101965193A (zh) 2006-11-15 2011-02-02 科达治疗公司 用于伤口愈合的改进方法和组合物
WO2008073479A2 (fr) 2006-12-11 2008-06-19 Coda Therapeutics, Inc. Compositions et traitements de cicatrisation de plaies aggravées
EP2237786A2 (fr) 2007-12-21 2010-10-13 Coda Therapeutics, Inc. Traitement d'états fibreux
EA201790434A1 (ru) 2014-08-22 2017-07-31 Окленд Юнисервисиз Лимитед Модуляторы каналов
EP3615575A4 (fr) 2017-04-28 2021-01-13 Auckland Uniservices Limited Méthodes de traitement et nouvelles constructions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284931A (en) * 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US5591623A (en) * 1990-08-14 1997-01-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
EP0558697A1 (fr) * 1991-06-28 1993-09-08 Massachusetts Institute Of Technology Therapie localisee utilisant des oligonucleotides
WO1993001286A2 (fr) * 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Therapie localisee utilisant des oligonucleotides
US5580969A (en) * 1992-07-24 1996-12-03 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ICAM-I RNA
WO1994022488A1 (fr) * 1993-04-01 1994-10-13 Isis Pharmaceuticals, Inc. OLIGONUCLEOTIDES ANTISENS INTERFERANT AVEC L'ACTIVITE DE COIFFE DE L'ARNm ET INHIBANT LA TRADUCTION
WO1996015780A1 (fr) * 1994-11-23 1996-05-30 Isis Pharmaceuticals, Inc. Compositions et procedes destines a la prevention et au traitement du rejet d'allogreffes

Also Published As

Publication number Publication date
WO1998024797A1 (fr) 1998-06-11
AU1564897A (en) 1998-06-29
JP2001505432A (ja) 2001-04-24
EP0950060A4 (fr) 2000-07-05
EP0950060A1 (fr) 1999-10-20

Similar Documents

Publication Publication Date Title
US5585479A (en) Antisense oligonucleotides directed against human ELAM-I RNA
US5773601A (en) Inverted chimeric and hybrid oligonucleotides
US6077833A (en) Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
CA2221448C (fr) Modulation par oligonucleotides antisens de l'expression de genes raf
US5650316A (en) Uses of triplex forming oligonucleotides for the treatment of human diseases
US5618709A (en) Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein
US20030022848A1 (en) Antisense oligonucleotide modulation of tumor necrosis factor-alpha (TNF-alpha) expression
US5652222A (en) Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides
US6300491B1 (en) Oligonucleotide inhibition of cell adhesion
WO1996018736A2 (fr) Procede et reactif servant a traiter les etats arthritiques, a introduitre une tolerance aux greffes et a inverser les reactions immunes
US5580969A (en) Antisense oligonucleotides directed against human ICAM-I RNA
US5596090A (en) Antisense oligonucleotides directed against human VCAM-1 RNA
WO1999054341A1 (fr) Modulation antisens amelioree de icam-1
CA2273203A1 (fr) Inhibition antisens de molecules d'adhesion humaines
CA2354188C (fr) Vaccin de cellules cancereuses
US5883082A (en) Compositions and methods for preventing and treating allograft rejection
WO1998014615A1 (fr) Modulation oligonucleotidique antisens de l'expression genique a glyproteine-p resistant a plusieurs drogues (mdr)
US5856099A (en) Antisense compositions and methods for modulating type I interleukin-1 receptor expression
US5612212A (en) Selective inhibition of cell proliferation by vav antisense oligonucleotides
WO1996015780A1 (fr) Compositions et procedes destines a la prevention et au traitement du rejet d'allogreffes
CA2223109A1 (fr) Utilisation d'oligonucleotides antisens complementaires de l'arnm du recepteur de l'interleukine-6 pour inhiber la proliferation cellulaire
JPH07501525A (ja) ｃ−ｍｙｂプロトオンコジーンに対するアンチセンスオリゴヌクレオチドによる黒色腫の処置
Tam et al. Biological availability and nuclease resistance extend the in vitro activity of a phosphorothioate-3′ hydroxypropylamine oligonucleotide
MXPA99005066A (en) Antisense inhibition of human adhesion molecules
KR19980702101A (ko) Cd28 발현의 조절을 위한 방법 및 조성물

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20050901